Press release
Idiopathic Pulmonary Fibrosis (IPF) Patient Pool Analysis Market New Product Development & Latest Trends
IntroductionIdiopathic Pulmonary Fibrosis (IPF) is a rare but progressive and fatal lung disease characterized by scarring of lung tissue, leading to breathing difficulties and declining quality of life. While the exact cause remains unknown, its burden on global healthcare systems has intensified in recent years due to aging populations, higher diagnosis rates, and improved disease awareness.
The global Idiopathic Pulmonary Fibrosis Patient Pool Analysis Market has gained importance for both healthcare providers and pharmaceutical companies. Patient pool analysis provides crucial data on prevalence, incidence, demographics, and treatment adoption rates, which directly influence clinical research, drug pipeline development, and healthcare resource planning.
In 2024, the global IPF patient pool is estimated at 650,000 patients, and by 2034, it is projected to exceed 950,000 patients, reflecting a compound annual growth rate (CAGR) of 3.8%. This growth is driven by better diagnostic technologies, increased screening programs, and rising awareness among clinicians and patients.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71520
Market Overview
• Patient Pool (2024): ~650,000 individuals worldwide
• Projected Patient Pool (2034): ~950,000 individuals
• CAGR (2024-2034): 3.8%
• Key Growth Drivers:
o Rising incidence of IPF among aging populations.
o Increasing use of high-resolution computed tomography (HRCT) for accurate diagnosis.
o Expanding clinical trial activity for novel therapies.
o Awareness campaigns by patient advocacy groups and healthcare organizations.
• Key Challenges:
o High cost of diagnosis and treatment.
o Limited availability of curative therapies; current drugs only slow progression.
o Misdiagnosis with other interstitial lung diseases (ILDs).
• Leading Players in IPF Treatments & Research: Roche, Boehringer Ingelheim, Bristol Myers Squibb, FibroGen, Gilead Sciences, Novartis, Galapagos NV, and Veracyte (diagnostics).
Segmentation Analysis
By Demographics
• Age Group:
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis (IPF) Patient Pool Analysis Market New Product Development & Latest Trends here
News-ID: 4170227 • Views: …
More Releases from Exactitude Consultancy

SSG Hospital launches an AI-powered oncology chatbot
The global AI in Oncology Market is rapidly emerging as one of the most transformative frontiers in healthcare, combining advanced machine learning, big data analytics, and clinical expertise to fight cancer. With oncology representing one of the most complex medical domains, artificial intelligence (AI) is reshaping how clinicians detect, diagnose, and treat cancer. AI is accelerating drug discovery, enhancing diagnostic imaging, enabling personalized treatment recommendations, and improving patient monitoring. As…

Orion and Abilita Therapeutics Announce Research Partnership to Create Next-Gene …
The global Next-Generation Antibody Therapeutics Market is experiencing rapid growth as pharmaceutical and biotechnology companies push the boundaries of antibody engineering to deliver safer, more effective, and highly targeted therapies. Unlike conventional monoclonal antibodies, next-generation formats-such as bispecific antibodies, antibody-drug conjugates (ADCs), antibody fragments, and engineered scaffolds-offer enhanced specificity, improved pharmacokinetics, and novel mechanisms of action. These innovations are revolutionizing treatment landscapes in oncology, autoimmune disorders, infectious diseases, and rare…

Prospects for the NAMPT Inhibitors Market in 2025-2034 | Pfizer Inc., Novartis A …
The NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitor Market is gaining momentum as researchers and biopharmaceutical companies explore novel therapeutic strategies targeting cellular metabolism and inflammatory pathways. NAMPT, a key enzyme in the NAD+ biosynthesis pathway, has been implicated in cancer cell survival, immune regulation, and metabolic disorders. Inhibitors of NAMPT have emerged as promising candidates for oncology, autoimmune conditions, and age-related diseases. With clinical trials expanding and increasing R&D investments, the NAMPT…

Acute lymphoblastic leukemia: a comprehensive review and 2025 latest update
Introduction
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow that primarily affects white blood cell precursors. While relatively rare compared to other cancers, it is the most common type of cancer in children, though it also affects adults, where prognosis is often poorer.
The management of ALL has improved significantly in recent decades due to advances in chemotherapy regimens, targeted therapies, and immunotherapies such as CAR-T…
More Releases for IPF
Cough in Idiopathic Pulmonary Fibrosis (IPF) Market Massive Growth opportunity A …
Introduction
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease characterized by scarring of the lung tissue, leading to declining lung function and breathing difficulties. Among its debilitating symptoms, chronic cough is one of the most distressing, affecting over 80% of IPF patients. Persistent cough significantly worsens patients' quality of life, disrupts sleep, and increases anxiety, yet therapeutic options remain limited.
The Cough in IPF Market is at a transformative stage,…
Idiopathic Pulmonary Fibrosis (IPF) Market Size, Share, Industry, Forecast and o …
Idiopathic Pulmonary Fibrosis (IPF) Market
Global Idiopathic Pulmonary Fibrosis (IPF) Market Set for Remarkable Growth, Projected to Reach US$ 4,614.3 Million by 2030
The global Idiopathic Pulmonary Fibrosis (IPF) market, valued at US$ 2,184.4 million in 2022, is poised for substantial expansion, with projections reaching up to US$ 4,614.3 million by 2030. Anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 10.1% during the forecast period from 2024 to 2031, the…
Breath of Hope: IPF Drug Pipeline Landscape (2022)
Market Outlook:
Breath of Hope: IPF Drug Pipeline Landscape (2022)
The IPF Drug Pipeline Landscape embarks on a transformative journey, offering a breath of hope for individuals grappling with Idiopathic Pulmonary Fibrosis (IPF). This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to reshape the trajectory of IPF treatment over the next decade.
Market Drivers:
Precision Therapies on the Horizon: At the forefront of the IPF Drug Pipeline, the prospect of…
Idiopathic Pulmonary Fibrosis (IPF) Market to Reach US$ 6,825.3 Million by 2033 …
The newly published report by IMARC Group, titled "Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the idiopathic pulmonary fibrosis (IPF) market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor…
Recent Release: Global Idiopathic pulmonary fibrosis (IPF) Market To 2023
MarketResearchReports.Biz presents this most up-to-date research on "Idiopathic pulmonary fibrosis (IPF)- Epidemiology Forecast To 2023"
Idiopathic pulmonary fibrosis (IPF) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Idiopathic pulmonary fibrosis (IPF) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Idiopathic pulmonary fibrosis (IPF) prevalent or incident cases segmented by age, sex and…
Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatm …
The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.
Browse the Report Summary at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
Insights on pipeline segments
As per the findings of research, it was found…